INVENUX, LLC
Biotech · Private
SCD-101, a botanical drug for oral treatment of sickle cell disease
- Grants
- $2.9M
- 5 awards
- Sector median: 1
- Raised
- —
- No Form D on record
- Contracts
- —
- No federal contracts on record
- Patents
- 4
- 0 granted · 4 pending
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓201620172018
| Date | Event | Source | Amount |
|---|---|---|---|
| Federal grant | Department of Health and Human Services · Phase II · Safety Studies for Clinical Trials of a Botanical Drug for Sickle Cell Disease | $1,499,750 | |
| Federal grant | Department of Health and Human Services · Phase I · Crossover Study of an Oral Treatment for Sickle Cell Disease | $224,950 | |
| Federal grant· 1 of 3 same day | Department of Health and Human Services · Phase I · Identification of the Antisickling Compounds in SCD-101 | $224,731 | |
| Federal grant· 2 of 3 same day | Department of Health and Human Services · Phase II · Safety Studies for Clinical Trials of a Botanical Drug for Sickle Cell Disease | $692,340 | |
| Federal grant· 3 of 3 same day | Department of Health and Human Services · Phase I · Identification of the Antisickling Compounds in SCD | $224,731 |
Federal grant · SBIR/STTR
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 2100 | Aspen Neuroscience | — | — |
| 2101 | Citryll | — | — |
| 2102 | Autolus Therapeutics | — | — |
| 2103 | INVENUX, LLC | — | — |
| 2104 | Legacy Lyfe Holdings, LLC | — | $5.3M |
| 2105 | Douleur Therapeutics Inc | — | — |
| 2106 | YEWSAVIN, INC. | — | — |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Patents
- Methods And Compositions For Controlling Neuroinflammationapplication
- Cannabinoids For Treating Neuroinflammationapplication
- Methods And Compositions For Preventing Or Reducing Neuroinflammationapplication
- Methods And Compositions For Controlling Neuroinflammationapplication
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.